OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 09:26 UTC. Every row links to its source record.

H3-3B H3.3 histone B

ENSG00000132475 · protein coding · Open Targets profile

Variant histone H3 which replaces conventional H3 in a wide range of nucleosomes in active genes. Constitutes the predominant form of histone H3 in non-dividing cells and is incorporated into chromatin independently of DNA synthesis. Deposited at sites of nucleosomal displacement throughout transcribed genes, suggesting that it represents an epigenetic imprint of transcriptionally active chromatin. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. {ECO:0000269|PubMed:14718166, ECO:0000269|PubMed:15776021, ECO:0000269|PubMed:16258499}.

In 14 of 15 cancers, the evidence for H3-3B comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751gliomagliomaglioma: germline 0.87breast carcinomabreast carcinomabreast carcinoma: somatic 0.46melanomamelanomamelanoma: somatic 0.30chondroblastomachondroblastomachondroblastoma: somatic 0.61superficial spreading melanomasuperficial spreading melanomasuperficial spreading melanoma: somatic 0.61nodular malignant melanomanodular malignant melanomanodular malignant melanoma: somatic 0.61cutaneous melanomacutaneous melanomacutaneous melanoma: somatic 0.61hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.46osteosarcomaosteosarcomaosteosarcoma: somatic 0.46lung carcinomalung carcinomalung carcinoma: somatic 0.46head and neck squamous cell carcinomahead and neck squamous cell carcinomahead and neck squamous cell carcinoma: somatic 0.46brain glioblastomabrain glioblastomabrain glioblastoma: somatic 0.46bile duct adenocarcinomabile duct adenocarcinomabile duct adenocarcinoma: somatic 0.46pancreatic ductal adenocarcinomapancreatic ductal adenocarcinomapancreatic ductal adenocarcinoma: somatic 0.46colon adenocarcinomacolon adenocarcinomacolon adenocarcinoma: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand
Antibody
GO CC high conf
PROTAC
UniProt Ubiquitination, Database Ubiquitination

gnomAD loss of function constraint: o/e 0.15272000432014465 (upper bound 0.4807499945163727). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of H3-3B's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of H3-3B's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.